Get the Stockscreener App
0.3249
0.25%
-0.000801
IGC Pharma Inc stock is traded at $0.3249, with a volume of 64,487.
It is down -0.25% in the last 24 hours and up +7.16% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.3257
Open:
$0.33
24h Volume:
64,487
Relative Volume:
0.24
Market Cap:
$25.89M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.2496
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
-3.56%
1M Performance:
+7.16%
6M Performance:
-12.90%
1Y Performance:
-35.02%
1-Day Range:
$0.3205
$0.332
1-Week Range:
$0.32
$0.335
52-Week Range:
$0.2525
$0.55
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3249 | 27.01M | 1.22M | -14.15M | -6.55M | -0.26 |
|
ONC
Beone Medicines Ltd Adr
|
247.45 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.39 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.42 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.45 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Sto - GuruFocus
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market - ACCESS Newswire
IGC Pharma Targets Puerto Rico's 12.5% Alzheimer's Rate in Strategic Trial Expansion - Stock Titan
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC - GuruFocus
IGCPharma (IGC) Confirms Genetic Safety of Alzheimer's Drug Ingr - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
Is IGC Pharma Inc (IGC) a good investment opportunity? - uspostnews.com
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Welcomes Strategic Investment from Advisors - PharmiWeb.com
IGC Pharma (IGC) Secures $475K Investment to Advance Alzheimer's Trial | IGC Stock News - GuruFocus
IGC Pharma Welcomes Strategic Investment from Advisors | IGC Sto - GuruFocus
IGC Pharma Welcomes Strategic Investment From Advisors - Barchart.com
The 7 Best Stocks Under 50 Cents To Buy For May 2025! - The Stock Dork
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporti - GuruFocus
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | IGC Stock News - GuruFocus
Former MassBio CEO Joins IGC Pharma's Advisory Board to Advance AI-Powered Alzheimer's Programs - Stock Titan
India Globalization Capital : IGC Announces Results of its 2020 Annual Stockholders Meeting - marketscreener.com
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - marketscreener.com
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Newswire.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - BioSpace
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma Accelerates Alzheimer's Breakthrough: Key Research Center Joins Phase 2 Trial - Stock Titan
IGC Pharma posts promising interim data for Alzheimer’s therapy - MSN
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - BioSpace
Breakthrough: New Alzheimer's Drug Cuts Sleep Disturbances by 78% in Phase 2 Trial - Stock Titan
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial - Clinical Trials Arena
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - BioSpace
IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy - MarketScreener
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - ACCESS Newswire
IGC Pharma's Alzheimer's Drug Shows Promise: CALMA Trial Adds New Florida Site - StockTitan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" - ACCESS Newswire
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):